MX2022010774A - Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. - Google Patents
Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.Info
- Publication number
- MX2022010774A MX2022010774A MX2022010774A MX2022010774A MX2022010774A MX 2022010774 A MX2022010774 A MX 2022010774A MX 2022010774 A MX2022010774 A MX 2022010774A MX 2022010774 A MX2022010774 A MX 2022010774A MX 2022010774 A MX2022010774 A MX 2022010774A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acids
- compositions
- treatment
- related diseases
- mitochondrial dysfunction
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004065 mitochondrial dysfunction Effects 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000001630 malic acid Substances 0.000 abstract 1
- 235000011090 malic acid Nutrition 0.000 abstract 1
- 230000008437 mitochondrial biogenesis Effects 0.000 abstract 1
- 230000004898 mitochondrial function Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Composición para promover la biogénesis mitocondrial y mejorar la función mitocondrial en un sujeto, la composición comprende un agente activo, dicho agente activo que contiene los aminoácidos leucina, isoleucina, valina, treonina, lisina y ácido cítrico, ácido succínico, ácido málico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102017000087359A IT201700087359A1 (it) | 2017-07-28 | 2017-07-28 | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010774A true MX2022010774A (es) | 2023-02-23 |
Family
ID=60628070
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001083A MX2020001083A (es) | 2017-07-28 | 2018-07-20 | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. |
MX2022010774A MX2022010774A (es) | 2017-07-28 | 2020-01-27 | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001083A MX2020001083A (es) | 2017-07-28 | 2018-07-20 | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. |
Country Status (22)
Country | Link |
---|---|
US (2) | US11337946B2 (es) |
EP (2) | EP3658132B1 (es) |
JP (2) | JP7266767B2 (es) |
KR (3) | KR20240063205A (es) |
CN (1) | CN110996935A (es) |
AU (2) | AU2018306540B2 (es) |
BR (1) | BR112020001471A2 (es) |
CA (1) | CA3070197A1 (es) |
CL (1) | CL2020000220A1 (es) |
DK (1) | DK3658132T3 (es) |
ES (1) | ES2923126T3 (es) |
HU (1) | HUE059050T2 (es) |
IT (1) | IT201700087359A1 (es) |
LT (1) | LT3658132T (es) |
MX (2) | MX2020001083A (es) |
MY (1) | MY200975A (es) |
PH (1) | PH12020500190A1 (es) |
PL (1) | PL3658132T3 (es) |
PT (1) | PT3658132T (es) |
RS (1) | RS63422B1 (es) |
SG (1) | SG11201912103TA (es) |
WO (1) | WO2019021135A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
IT201900002109A1 (it) * | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
JP2021038147A (ja) * | 2019-08-30 | 2021-03-11 | 国立大学法人 鹿児島大学 | ミトコンドリア生合成促進剤 |
IT202000000454A1 (it) * | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro |
IT202000000442A1 (it) * | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
IT202000021664A1 (it) * | 2020-09-14 | 2022-03-14 | Iaf Network S P A | Formulazione amminoacidica bilanciata |
TW202308604A (zh) * | 2021-05-10 | 2023-03-01 | 國立大學法人東北大學 | 肌肉量增加用組成物 |
IT202100029726A1 (it) * | 2021-11-24 | 2023-05-24 | Professional Dietetics Spa | Composizioni oftalmiche per il trattamento di lesioni corneali |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1032403B1 (en) * | 1997-10-24 | 2012-05-02 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
ITTO20010580A1 (it) * | 2001-06-15 | 2002-12-15 | Professional Dietetics Srl | Composizioni a base di aminoacidi per il miglioramento della funzioneventricolare miocardica in pazienti affetti da diabete. |
ITTO20010804A1 (it) | 2001-08-08 | 2003-02-08 | Professional Dietetics Srl | Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl |
US6620850B2 (en) | 2001-09-19 | 2003-09-16 | University Of Florida | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors |
US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
ITTO20030789A1 (it) | 2003-10-07 | 2005-04-08 | Professional Dietetics Srl | Composizione a base di amino acidi per il trattamento |
WO2007049818A1 (ja) | 2005-10-27 | 2007-05-03 | Ajinomoto Co., Inc. | 抗脂肪肝、抗肥満及び抗高脂血症用組成物 |
US7982066B2 (en) * | 2005-12-09 | 2011-07-19 | Novalife, Inc. | High protein supplement |
JP2007161642A (ja) | 2005-12-14 | 2007-06-28 | Kyowa Hakko Kogyo Co Ltd | アルコール性肝障害抑制剤 |
CN103347511B (zh) | 2011-02-17 | 2016-04-27 | 味之素株式会社 | 化学治疗剂的抗肿瘤活性的增强剂 |
TW201311234A (zh) | 2011-04-28 | 2013-03-16 | Ajinomoto Kk | 抗癌劑副作用改善用組成物 |
US20130084378A1 (en) | 2011-09-30 | 2013-04-04 | Daesang Corporation | Amino acid seasoning compositions comprising l-glutamic acid and l-lysine |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US20160038565A1 (en) | 2012-06-15 | 2016-02-11 | Gencia Corporation | Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy |
CN102772407B (zh) | 2012-08-01 | 2014-09-17 | 岳茂兴 | 一种促进神经损伤修复的药物组合物及其应用 |
US9597367B2 (en) * | 2013-04-19 | 2017-03-21 | Bioventures, Llc | Methods for improving muscle and heart function |
CN106999521A (zh) | 2014-12-09 | 2017-08-01 | 株式会社日本自然发酵 | 老化抑制剂 |
MX357998B (es) * | 2015-03-20 | 2018-07-11 | Antonio Hernandez Miramontes Jorge | Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo. |
WO2016179657A1 (en) * | 2015-05-11 | 2016-11-17 | Newcastle Innovation Limited | Amino acid supplementation |
JP6773269B2 (ja) | 2015-05-14 | 2020-10-21 | プロフェッショナル ダイエテティクス エス.ピー.エー. | 放射線療法および/または化学療法を受けている腫瘍患者における粘膜炎の治療における使用のためのアミノ酸を備える組成物 |
WO2017020121A1 (en) | 2015-07-31 | 2017-02-09 | Val-Chum, Limited Partnership | Glycerol-3-phosphate phosphatase activators |
EP3379946A1 (en) | 2015-11-27 | 2018-10-03 | DoubleGood AB | Food supplement and composition for treating the metabolic syndrome |
JP2020517703A (ja) | 2017-04-28 | 2020-06-18 | アクセラ・ヘルス・インコーポレイテッドAxcella Health Inc. | アミノ酸組成物及び外傷性脳損傷の治療のためのそれらの使用 |
IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
US20200323820A1 (en) | 2017-10-02 | 2020-10-15 | University Of Florida Research Foundation, Incorporated | Materials and methods for inhibiting tumor growth |
EP3763363A4 (en) * | 2018-03-05 | 2021-11-10 | Ajinomoto Co., Inc. | COMPOSITION TO IMPROVE COGNITIVE FUNCTION, COMPOSITION TO TREAT SYMPTOMS OF ANXIETY AND COMPOSITION TO SUPPRESS BRAIN ATROPHY |
IT201800006725A1 (it) | 2018-06-27 | 2019-12-27 | Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche | |
IT201900002109A1 (it) | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
US20220394508A1 (en) | 2019-11-11 | 2022-12-08 | Lg Electronics Inc. | Vehicular distributed antenna system operating in wireless communication system and method for operating same |
IT202000000454A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro |
IT202000000442A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
WO2022266480A1 (en) | 2021-06-17 | 2022-12-22 | Axcella Health Inc. | Methods of predicting liver fat content and uses thereof |
-
2017
- 2017-07-28 IT IT102017000087359A patent/IT201700087359A1/it unknown
-
2018
- 2018-07-20 WO PCT/IB2018/055425 patent/WO2019021135A1/en active Application Filing
- 2018-07-20 KR KR1020247014645A patent/KR20240063205A/ko active Application Filing
- 2018-07-20 CN CN201880047542.0A patent/CN110996935A/zh active Pending
- 2018-07-20 HU HUE18753465A patent/HUE059050T2/hu unknown
- 2018-07-20 PL PL18753465.6T patent/PL3658132T3/pl unknown
- 2018-07-20 MX MX2020001083A patent/MX2020001083A/es unknown
- 2018-07-20 KR KR1020237026054A patent/KR20230117642A/ko not_active IP Right Cessation
- 2018-07-20 US US16/634,330 patent/US11337946B2/en active Active
- 2018-07-20 BR BR112020001471-0A patent/BR112020001471A2/pt unknown
- 2018-07-20 EP EP18753465.6A patent/EP3658132B1/en active Active
- 2018-07-20 AU AU2018306540A patent/AU2018306540B2/en active Active
- 2018-07-20 KR KR1020207003492A patent/KR102566297B1/ko active IP Right Grant
- 2018-07-20 JP JP2019566579A patent/JP7266767B2/ja active Active
- 2018-07-20 LT LTEPPCT/IB2018/055425T patent/LT3658132T/lt unknown
- 2018-07-20 SG SG11201912103TA patent/SG11201912103TA/en unknown
- 2018-07-20 MY MYPI2020000106A patent/MY200975A/en unknown
- 2018-07-20 CA CA3070197A patent/CA3070197A1/en active Pending
- 2018-07-20 RS RS20220627A patent/RS63422B1/sr unknown
- 2018-07-20 PT PT187534656T patent/PT3658132T/pt unknown
- 2018-07-20 DK DK18753465.6T patent/DK3658132T3/da active
- 2018-07-20 EP EP21174744.9A patent/EP3915553A1/en active Pending
- 2018-07-20 ES ES18753465T patent/ES2923126T3/es active Active
-
2020
- 2020-01-27 MX MX2022010774A patent/MX2022010774A/es unknown
- 2020-01-27 PH PH12020500190A patent/PH12020500190A1/en unknown
- 2020-01-27 CL CL2020000220A patent/CL2020000220A1/es unknown
-
2022
- 2022-04-20 US US17/724,537 patent/US11957651B2/en active Active
-
2023
- 2023-03-08 JP JP2023035509A patent/JP7513311B2/ja active Active
- 2023-11-14 AU AU2023266256A patent/AU2023266256A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010774A (es) | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. | |
MX2019015311A (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
MX2017013983A (es) | Uso de agentes activos durante tratamientos quimicos. | |
PH12020552254A1 (en) | Compositions comprising amino acids for use in the prevention and treatment of liver diseases | |
EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
MY192532A (en) | Liquid pharmaceutical composition | |
MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
PH12020500189A1 (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases | |
MX2018008545A (es) | Composicion antibacteriana y metodo para tratar infecciones por estafilococos con la composicion antibacteriana. | |
MY187022A (en) | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy | |
CR20190298A (es) | Amidas aromáticas de ácido carboxílico | |
MX2021006488A (es) | Composiciones para mejorar la funcion sexual. | |
WO2018094023A3 (en) | Cyclic dipeptides and wound healing | |
PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
CL2022001779A1 (es) | Composiciones que comprenden aminoácidos para la prevención y/o el tratamiento del cáncer | |
MX2021009344A (es) | Composiciones con aminoacidos para el uso y tratamiento de lesiones del sistema nervioso central. | |
NZ728962A (en) | Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia | |
PH12016501448A1 (en) | Antifungal composition | |
EP3338792A4 (en) | CORNEAL LESION PREVENTION / TREATMENT COMPOSITION COMPRISING ACTIVE PRINCIPLES OF THYMOSINE BETA 4 AND CITRIC ACID | |
NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease | |
PH12018502568A1 (en) | Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections | |
EP3158989A3 (en) | Cosmetic skin treatment composition | |
MX2023005681A (es) | Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol. | |
AR107264A1 (es) | Composiciones cosméticas que comprenden una combinación sinérgica de partículas absorbentes y adsorbentes de sudor y usos de las mismas | |
MY173606A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease |